New Blood-Cleaning machine could help liver failure patients avoid transplant

NCT ID NCT07329036

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a combined blood-filtering system (DPMAS and plasma exchange) in 25 adults with acute-on-chronic liver failure who are either waiting for a liver transplant or not eligible for one. The goal is to see if this artificial liver support can keep patients alive without a transplant for at least 21 days. The treatment aims to remove toxins from the blood and support vital organ function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Double Plasma Molecular Adsorption System (DPMAS) combined with Therapeutic Plasma Exchange (TPE)
What this could lead to
If it works, this could provide a temporary liver support option for patients with acute liver failure, potentially reducing the need for urgent liver transplants.
What could go wrong
This is a small early study with only 25 participants, so results may not apply broadly. The treatment is supportive, not a cure, and risks include bleeding or infection from the blood-filtering procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LIVER FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institute for Clinical and Experimental Medicine (IKEM)

    RECRUITING

    Prague, 14200, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.